According to a research report published this morning, Bank of America has increased Integra Lifesciences' IART PO from $26 to $36.
In the report, Bank of America said, "IART has recently run through our PO. and given our view that earnings expectations are now low enough, and given our sense that end markets are stable we are raising our PO on IART to $36. Today, IART trades at 13.5x our 2013 estimate (we include amortization expense) and 7.6x EBITDA. On EBITDA, IART trades directly in line with many other medtech stories with mid-single digit revenue growth prospects."
Bank of America maintains its Neutral rating on Integra Lifesciences, which closed yesterday at $32.39.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in